Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Microbot Medical ( (MBOT) ) has issued an update.
On January 21, 2025, Microbot Medical Inc. appointed Ms. Michal Ahuvia as Director of Operations to enhance production efficiencies ahead of the anticipated second-quarter launch of their LIBERTY® system. This strategic move aims to strengthen the company’s operational capabilities, crucial for its commercial strategy and future success, as commented by CEO Harel Gadot.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on improving the quality of care globally. The company has developed the LIBERTY® Endovascular Robotic System, the first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to accessing advanced robotic systems.
YTD Price Performance: 43.86%
Average Trading Volume: 2,418,344
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $45.97M
See more insights into MBOT stock on TipRanks’ Stock Analysis page.
